Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data

被引：0

作者：

Wolinsky, J. S. ^{[1
]}

Brochet, B. ^{[2
]}

Hartung, H. -P. ^{[3
,4
]}

Naismith, R. T. ^{[5
]}

Airas, L. ^{[6
]}

Coutant, K. ^{[7
]}

Koendgen, H. ^{[7
]}

Manfrini, M. ^{[7
]}

Mehta, L. ^{[8
]}

Prajapati, K. ^{[9
]}

Kappos, L. ^{[10
]}

机构：

[1] McGovern Med Sch, Houston, TX USA

[2] Univ Bordeaux, Bordeaux, France

[3] Heinrich Heine Univ Dusseldorf, Ctr Neurol & Neuropsychiat, Dusseldorf, Germany

[4] Heinrich Heine Univ Dusseldorf, LVR Klinikum, Dusseldorf, Germany

[5] Washington Univ, Sch Med, St Louis, MO USA

[6] Univ Turku, Div Clin Neurosci, Turku, Finland

[7] F Hoffmann La Roche Ltd, Basel, Switzerland

[8] Genentech Inc, San Francisco, CA 94080 USA

[9] GCE Solut Inc, Amsterdam, Netherlands

[10] Univ Hosp Basel, Basel, Switzerland

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

159

引用

页码：56 / 57

页数：2